Collaboration is at the heart of our approach. We believe the bigger the challenge, the bigger the need for collaboration.
We are seeking partners across the life science ecosystem, from pharmaceutical companies and investors to government agencies, contract research organizations, and academic institutions, to advance and commercialize our pipeline targeting the world's highest-priority resistant pathogens.
Work with us →
Fedora is open to a range of partnership structures across our anti-infective programs.
License a program or co-develop it with us toward the clinic and market.
Regional and global commercialization partnerships for our assets.
Equity and financing to accelerate development of the pipeline.
Government-supported development programs and non-dilutive funding.
Partnerships that advance our platform and discovery technologies.
Joint research with academic and industry partners on resistant pathogens.
| Program | Target / Indication | Stage | Partnering status |
|---|---|---|---|
| Nacubactam | Multidrug-resistant bacterial infections | Phase 3 – completed | Available for partnership |
| FPI-2119 | Multidrug-resistant bacterial infections | Pre-clinical | Available for partnership |
| Other programs | Various | Discovery | Available for collaboration |
Comprehensive novel pipeline: A rich pipeline of anti-infective programs with robust patent protection for all major markets.
Experienced leadership and scientific advisory board: Fedora Pharmaceuticals was founded by a team whose contributions have helped shape the modern treatment of resistant bacterial infections. The team has extensive global experience in anti-infective therapy discovery and development since the 1980s.
Proven scientific and commercial validation: Recognition at leading global conferences through posters and presentations. Our team contributed to the discovery of tazobactam, one of the most successful and widely used β-lactamase inhibitors ever developed. Building upon this legacy, our team independently discovered nacubactam, which is anticipated to enter the Japanese market within a year.
Tell us a little about yourself and your area of interest, and our team will be in touch.
